A Case Report of Post-Covid Mucormycosis of Mandible

  • Mrunmayee Shrikant Durugkar Private Practitioner, Department of Oral Medicine and Radiology, Maharashtra, India.
  • Swati Jadhav Private Practitioner, Department of Oral Medicine and Radiology, Maharashtra, India.
  • Mahendra Patait Professor and HOD, Department of Oral Medicine and Radiology, SMBT Dental College and Hospital, Sangamner, Maharashtra, India.
  • Sushilkumar Bagul Associate Professor, Department of Oral and Maxillofacial Surgery, SMBT Dental College and Hospital, Sangamner, Maharashtra, India.
Keywords: Fungal, COVID Associated Mucormycosis, Mandible, Mucormycosis

Abstract

The coronavirus disease 2019 (COVID-19) has affected the world and has been considered a pandemic disease. It came with the risk of co-infections. Mucormycosis is one of them. It is a severe fungal infectious disease. Mucormycosis in COVID-19 patients presented an additional challenge for health care. It is considered that coronavirus disease 2019 patients having uncontrolled diabetes, high‑dose steroid therapy, and exposure to mechanical ventilation have developed mucormycosis. Amphotericin B is the drug of choice for mucormycosis, also posaconazole or isavuconazole is used for step‑down therapy and salvage therapy. It was commonly seen in paranasal sinues among which the maxillary sinus was a common site. This case report presents the case of mucormycosis of the mandible in a patient with having history of COVID–19.

References

Kaushik A, Jaiswal A, Pandey HS, Singh P. Mucormycosis and COVID-19: A systemic review. Medical Journal of Dr. DY Patil Vidyapeeth. 2022 Nov 1;15(8):163. doi: http://dx.doi.org/10.4103/mjdrdypu.mjdrdypu_359_21

Swain SK, Jena PP. Coronavirus disease 2019-associated mucormycosis of the head-and-neck area: A new rise of dreaded black fungus in the current pandemic. Journal of the Scientific Society. 2022 Sep 1;49(3):223. doi: http://dx.doi.org/10.4103/jss.jss_56_21

Sannathimmappa MB, Nambiar V, Aravindakshan R. Storm of a rare opportunistic life threatening mucormycosis among post COVID-19 patients: A tale of two pathogens. International Journal of Critical Illness and Injury Science. 2022 Jan;12(1):38. doi: https://doi.org/10.4103%2Fijciis.ijciis_48_21

Walther G, Wagner L, Kurzai O. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. Journal of fungi. 2019 Nov 14;5(4):106. doi: https://doi.org/10.3390/jof5040106

Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021 May;186(2):289-98. doi: https://doi.org/10.1007/s11046-021-00528-2

Sutradhar J, Sarkar BR. Manifestations and risk factors of COVID-19 and mucormycosis: A mini-review. Journal of Acute Disease. 2021 Nov 1;10(6):221. doi: https://doi.org/10.4103/2221-6189.330739

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020 Feb 15;395(10223):507-13. doi: https://doi.org/10.1016/s0140-6736(20)30211-7

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. Journal of fungi. 2020 Nov 2;6(4):265. doi: https://doi.org/10.3390/jof6040265

Choudhary NK, Jain AK, Soni R, Gahlot N. Mucormycosis: A deadly black fungus infection among COVID-19 patients in India. Clinical epidemiology and global health. 2021 Oct 1;12:100900.doi: https://doi.org/10.1016/j.cegh.2021.100900

Kaushik A, Jaiswal A, Pandey HS, Singh P. Mucormycosis and COVID-19: A systemic review. Medical Journal of Dr. DY Patil Vidyapeeth. 2022 Nov 1;15(8):163. doi: https://doi.org/10.4103/mjdrdypu.mjdrdypu_359_21

Chamola V, Mohammadi R, Nair H, Goyal A, Patel A, Hassija V, Bassetti M, Narang P, Paredes R, Santos JR, Hashemi SJ. COVID-19-associated mucormycosis: A review of an emergent epidemic fungal infection in the era of COVID-19 pandemic. Journal of Research in Medical Sciences. 2022 Jan 1;27(1):27-57. doi: https://doi.org/10.4103/jrms.jrms_1090_21

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. The American journal of emergency medicine. 2021 Apr 1;42:264-e5. doi: https://doi.org/10.1016/j.ajem.2020.09.032

Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. Journal de mycologiemedicale. 2020 Jun 1;30(2):100971. doi: https://doi.org/10.1016%2Fj.mycmed.2020.100971

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet infectious diseases. 2019 Dec 1;19(12):e405-21. doi: https://doi.org/10.1016/s1473-3099(19)30312-3

Published
2023-11-10
How to Cite
Shrikant Durugkar, M., Jadhav, S., Patait, M., & Bagul, S. (2023). A Case Report of Post-Covid Mucormycosis of Mandible. International Journal Of Drug Research And Dental Science, 5(3), 29-36. https://doi.org/10.36437/ijdrd.2023.5.3.D